Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules

The 4-component vaccine 4CMenB, developed against invasive disease caused by meningococcal serogroup B, is approved for use in infants in several countries worldwide. 4CMenB is mostly used as 3 + 1 schedule, except for the UK, where a 2 + 1 schedule is used, and where the vaccine showed an effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Biolchi, Alessia, Tomei, Sara, Santini, Laura, Welsch, Jo Anne, Toneatto, Daniela, Gaitatzis, Nikolaos, Bai, Xilian, Borrow, Ray, Giuliani, Marzia Monica, Mori, Elena, Pizza, Mariagrazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605712/
https://www.ncbi.nlm.nih.gov/pubmed/30352000
http://dx.doi.org/10.1080/21645515.2018.1537756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605712/
https://www.ncbi.nlm.nih.gov/pubmed/30352000
http://dx.doi.org/10.1080/21645515.2018.1537756

Ejemplares similares